Introduction
The capacity to selectively modulate immune responses has profound implications for human health. Vaccine strategies designed to induce pathogen-specific immune responses are relatively well established, whereas strategies to selectively prevent or abolish unwanted antigen-specific immunological responses present a substantial ongoing research challenge. The ability to selectively induce tolerance could be applied not only to the treatment of autoimmunity, allergy and transplantation, but also to the prevention of undesired immune responses against other developing therapeutic modalities, such as enzyme replacement and gene therapy. The latter use could encompass the induction of tolerance to both the antigenic constituents of recombinant gene transfer systems and to the encoded therapeutic transgene products.
In addition to posing novel immunological challenges, viral vectors engineered for gene therapy application are providing a powerful new set of reagents for selectively regulating immune responses. [1] [2] [3] [4] [5] Such vectors often retain the natural adjuvanticity of the infectious agent from which they were derived, but in addition they may possess biological properties that avoid or subvert immunological responses. Understanding the immunobiological properties of individual vector systems and carefully exploiting them in the context of specific applications are key requirements for progress.
Recombinant vectors derived from the nonpathogenic parvovirus, adeno-associated virus (rAAV), are immensely promising both as gene transfer vectors and tools for selective immune modulation. Early reports targeting muscle, a highly immuno-stimulatory environment, showed long-term transgene expression of 'nonself' proteins in the cytosol of cells in immune competent animals, 6 -8 a consequence of inefficient dendritic cell transduction 9 and minimal stimulation of innate immunity. 10 These features, together with the capacity to package vector genomes into an increasing number of capsid serotypes with broad tissue tropism, 11 render these vectors conducive to use in gene therapy applications. The system is also receiving attention as a platform for genetic vaccines. [12] [13] [14] [15] [16] [17] [18] This seemingly paradoxical application stems from the observed transgenespecific immune responses stimulated by the vector in certain models where the transgene is expressed at the cell surface, 19 secreted [20] [21] [22] [23] [24] or packaged into certain capsid serotypes. 16 Indeed, by recognizing the potential immunogenicity of rAAV, clinical trials for factor IX deficiency have precluded patients whose genetic mutation results in undetectable or dramatically truncated protein expression, 25 as there is an increased likelihood of neutralizing antibody responses that block the activity of the vector-encoded FIX. [20] [21] [22] We have been investigating the possibility of developing rAAV as a genetic vaccine vector and hypothesized that the desired immune response could be programmed into a vector with minimal inherent immunogenicity through the incorporation of carefully selected genetic elements or adjuvants. In an earlier study, we have shown that the intramuscular delivery of AAV pseudoserotype 1 vectors (rAAV1) encoding secreted malarial antigens can stimulate humoral immunity, but these are insufficient in magnitude to protect from a parasite challenge. 26 In an effort to augment these responses, we genetically modified the vector by fusing antigens to the C-terminus of CTLA4-Ig, a molecule that can bind B7 costimulatory molecules at the surface of antigenexpressing cells 27 and that has been approved for the treatment of rheumatoid arthritis in the clinic. 28 Antigen fusion with CTLA4-Ig augments humoral immune responses to DNA vaccines some 10 000-fold, presumably through the targeting of low antigen concentrations to antigen-presenting cells that initiate and promote these responses. [29] [30] [31] Consistent with this observation, we have found that the intramuscular injection of low doses of rAAV1 fusion vectors augmented antibody responses to the antigen in a manner dependent on CTLA4-Ig binding with B7 molecules. In marked contrast, however, higher doses induced long-lived antigen-specific humoral tolerance in a B7-independent manner, effectively inhibiting antibody responses to the fused antigen, while permitting normal responsiveness to unfused antigens. In addition to holding possibilities for further development of rAAV as a gene delivery vector, our data indicate that CTLA4-Ig fusion with the rAAV transgene product enables the immunological responses to be broadly modulated from immunity to tolerance and creates exciting therapeutic possibilities.
Results

In vitro characterization of rAAV CTLA4Ig fusion vector
The vector rAAV-CTLA4-Ig-MSP4/5 ( Figure 1a ) encoding Plasmodium yoelii merozoite surface protein 4/5 (MSP4/5) fused to CTLA4-Ig was initially tested in HEK-293 cells. Western analysis of culture supernatant for MSP4/5 under reducing and nonreducing conditions detected 90 and 180 kDa protein species, respectively, indicating that the CTLA4-Ig-MSP4/5 fusion protein was of the expected size and formed a dimer (Figure 1b) by virtue of the IgG 1 hinge domain. Similar signals were not detected in supernatants collected from cells transduced with a control vector, rAAV-GFP (green fluorescent protein; data not shown). Importantly, the ability of the vector-encoded CTLA4-Ig-MSP4/5 fusion protein to bind CD80 and CD86 was confirmed using gene-modified HEK-293 cells expressing these molecules (Figures 1c and d) . 10 vg produced the highest responses with increasing antibody levels first detected 2 weeks after vector administration (Figure 2a) . At higher vector doses, there was more rapid induction of humoral immunity, but this was followed by a paradoxical decline in antibody levels. Indeed, at the highest dose of 10 12 vg, antibody was not detected 2 weeks after vector administration.
In contrast to the CTLA4-Ig-fusion vector, rAAV1-MSP4/5 was substantially less immunogenic at low doses and more immunogenic at high doses (Figure 2b ). At 10 9 vg, no antibody responses to MSP4/5 were detected, whereas increasing doses through to 10 12 vg induced progressively higher antibody responses. The responses stimulated with 10 11 vg of rAAV-MSP4/5 and 10 9 vg of rAAV-CTLA4Ig-MSP4/5 were equivalent, despite the two orders of magnitude difference in dose (Figure 2c ), indicating that the fusion of CTLA4-Ig to MSP4/5 augmented the humoral immune response 100-fold at low vector doses.
The rapid induction and subsequent decline in MSP4/5-specific antibodies after high-dose rAAV-CTLA4-Ig-MSP4/5 (10 12 vg) was further analyzed by the characterization of the antibody isotype response. The CTLA4-Ig fusion vector stimulated high IgG 1 and low IgM at 1-week post-injection (Figure 2d ), indicating antibody stimulation and class switching. In contrast, the response to rAAV-MSP4/5 was markedly slower with IgM predominantly detectable at week 1 followed by a marked increase in IgG 1 and a modest increase in all other antibody isotypes at week 2. Collectively, these data indicate that low-dose CTLA4-Ig fusion vector is immunostimulatory, whereas high-dose CTLA4-Ig fusion vector stimulates a more rapid but abortive antibody response. Unresponsiveness induced by high-dose CTLA4-Ig fusion vector was long-lasting, and persisted at least 26 weeks after injection, the longest interval tested (data not shown). Tolerance was not due to nonspecific effects of the rAAV1 vector, as secondary antigen challenge of rAAV1-GFP-injected control mice produced humoral responses to MSP4/5 or HEL in adjuvant that were identical to uninjected controls (data not shown).
To determine whether tolerance could be induced to a second model antigen, the sequence encoding MSP4/5 in the fusion vector was replaced with one encoding HEL. In vitro characterization of the rAAV-CTLA4-Ig-HEL transgene product confirmed that this molecule formed a dimer of the expected size and bound B7 molecules (data not shown). Injection of mice with rAAV1-CTLA4-Ig-HEL stimulated HEL-specific antibody responses in a dose-dependent manner that followed similar kinetics to anti-MSP4/5 responses induced by rAAV1-CTLA4-Ig-MSP4/5 ( Figure 4a ). Injection of mice with HEL in adjuvant 10 weeks post-vector delivery showed markedly reduced secondary responses in high-dose treated mice, when compared with primary responses in naïve control animals ( Figure 4b ). The antigenic specificity of rAAV1-CTLA4-Ig-HEL treatment was shown when responses to codelivered recombinant MSP4/5 in adjuvant were observed at a similar magnitude in both groups (data not shown). Furthermore, lower vector doses of 10 9 and 10 10 vg per mouse primed the highest secondary responses to HEL (Figure 4c ), thereby validating the immune augmentation effect of low-dose CTLA4-Ig fusion vector. Collectively, these data indicate that the intramuscular delivery of rAAV1-encoding CTLA4-Ig fusion molecules specifically promotes or terminates humoral responses to the fused antigen, in a dosedependent manner, with high doses capable of inducing a state of long-lasting antigen-specific tolerance.
Tolerance induction by rAAV1 vectors encoding CTLA4-Ig fusion molecules is independent of B7 binding CTLA4-Ig has been shown to bind B7 molecules, CD80 and CD86, and to impair immunity through B7 blockade. 27, 32 To explore the involvement of this mechanism in tolerance induction in our model, the B7-binding domain in the CTLA4-Ig fusion vector was mutated to produce rAAV-DCTLA4-Ig-MSP4/5, and the inability of the resultant transgene product to bind CD80 and CD86 was confirmed in vitro (data not shown). Unlike the parent vector with the B7-binding domain intact (Figure 5a ), 10 9 vg per mouse of rAAV1-DCTLA4-Ig-MSP4/5 failed to augment immunity (Figure 5b ), in keeping with the loss of antigen targeting to B7-expressing antigen-presenting cells. At the highest dose of 10 12 vg, however, responses to the mutated vector remained low to undetectable, and the characteristic appearance and termination of anti-MSP4/5 antibodies at early time points, observed with the parent vector, were absent (Figure 5b ). Importantly, tolerance was induced with 10 12 vg of rAAV1-DCTLA4-Ig-MSP4/5, as indicated by reduced secondary responses to MSP4/5 in IFA (Figure 5c ), whereas responses to codelivered HEL were unaffected (data not shown), confirming the specificity of this effect. Unexpectedly, these data show rAAV vaccines for humoral tolerance or immunity GJ Logan et al that tolerance induction in our model is independent of B7 binding.
Sera from mice receiving 10 12 vg, collected prior to secondary antigen delivery, were analyzed to determine whether there were any differences in the amount of transgene product between the two groups. Mice receiving rAAV1-CTLA4-Ig-MSP4/5 showed a slow but progressive rise in fusion molecule over 10 weeks, reaching a concentration of 20 ng ml À1 (Figure 5d ). In contrast, a similar dose of rAAV1-DCTLA4-Ig-MSP4/5 produced a dramatic rise in DCTLA4-Ig-fusion molecule 1 week after vector delivery, which had disappeared by the second week (Figure 5d ). Over the ensuing 8 weeks, the transgene products in this group continued to rise at a greater rate than in the group receiving the nonmutated molecule and were at least five-fold greater at completion of the experiment. These differences may have been due to the differential immune clearance of transgene products and a similar study was therefore conducted in immunodeficient animals (IL-2Rgc
). This showed no substantial differences in the serum concentration of transgene products 1 week after vector delivery (Figure 5e ), although the levels obtained were of a higher order of magnitude than those observed in immune competent mice and were sustained over the course of the experiment. Collectively, these data indicate that CTLA4-Ig-fusion molecules are cleared from the circulatory system in immune competent mice and that B7-binding transgene products are cleared at a greater rate, presumably through antibody clearance and/or sequestration by B7-expressing antigen-presenting cell. Figure 6a ). Similar differences in antigen levels were also observed with vectors encoding HEL (data not shown). Altogether, these data are consistent with CTLA4-Ig fusion exerting both transcriptional and posttranscriptional effects. To further define the elements responsible, a number of additional constructs were prepared and evaluated (Figures 6b and d) . Removal of intronic sequences present in the CTLA4-Ig-MSP4/5 vector construct (Figure 1a) did not reduce the resultant antigen expression levels (Figure 6b ). However, substitution of the IgG 1 hinge and Fc domain with the hinge region from IgG 3 reduced protein expression to levels observed with unfused MSP4/5 protein (Figure 6b) . Involvement of the IgG 1 hinge and Fc domain was further supported when insertion of this region into the unfused vector substantially increased transgene expression (TPA-Ig-MSP4/5, TPA, tissue plasminogen activator leader, Figure 6b) . Finally, the possible involvement of the Ig recycling protein, FcRn, expressed in both HEK-293 and NIH3T3 cells (Figure 6c) , was excluded as sitedirected mutagenesis of the FcRn-binding domain on the CTLA4-Ig fusion molecule did not affect protein expression (Figure 6d ). rAAV vaccines for humoral tolerance or immunity GJ Logan et al
Discussion
The development of gene transfer systems that also modulate immunity offers novel opportunities not only for the design of genetic vaccines, effective against infectious agents, but also for the prevention of undesirable responses that underlie autoimmunity, allergy, transplantation and even responses that interfere with gene therapy strategies. The challenges for tolerogenic 'vaccine' design are further heightened by a requirement for exquisite specificity while allowing normal immunological function against other antigenic determinants encountered by the immune system. The development of these vector systems is appealing, as current protocols to induce and maintain immune tolerance are limited and generally involve the continual administration of antigen. This was first shown half a century ago, 33 and advanced only recently through the use of chemically synthesized peptides and altered peptide ligands. 34 However, these strategies are not without their limitations and in some instances have primed for immune responses rather than induced tolerance. 34, 35 This study advances rAAV as a genetic vaccine system for the purposes of either immune stimulation or humoral tolerance induction. Genetic fusion of the rAAV1-encoded antigen with the genetic adjuvant CTLA4-Ig altered immunological responses, so that at low doses (10 9 vg), the vector augmented antibody responses 100-fold in a B7-dependent manner. This finding is in keeping with those obtained in plasmid vaccine systems, [29] [30] [31] the only other vector used to explore the CTLA4-Ig-Ag fusion strategy, and offers an opportunity for improving rAAV genetic vaccines to prime and/or boost responses to provide immunity against cancer and infectious diseases. In contrast, however, higher doses of the vector (10 12 -10 13 vg) induced long-lasting antigen-specific tolerance in a B7-independent manner, effectively inhibiting antibody responses to the fused antigen while permitting normal responsiveness to unfused antigens. This latter finding was unexpected, as neutralizing antibody responses to the therapeutic molecule have hampered studies exploring the utility of rAAV for muscle delivery of secreted transgene products. [20] [21] [22] [23] [24] 36 An immediate clinical application for this finding is, therefore, in the prevention of antibody responses that can neutralize recombinant protein or gene therapies, as is the case with blood factor infusions and viral vector systems. In addition, it is conceivable that the recombinant fusion molecules might simultaneously retain biological activity as well as induce humoral tolerance, thus creating a more powerful gene therapy vector system. It is important to note that our CTLA4-Ig fusion vector currently lacks an important epitope (His435) for IgG to interact with FcRn, 37 a molecule involved in IgG 'recycling' and sustaining higher serum concentrations of IgG-fused therapeutics. In addition to the above findings, this study has also made the unexpected observation that antigen fusion with CTLA4-Ig can enhance antigen expression approximately 10-fold, an effect mapped to the hinge and Fc domain of IgG 1, but not involving FcRn. This could be a consequence of the observed two-to threefold increase in transgene transcriptional activity, although this does not fully account for the enhancement in protein expression (48-fold). Superior protein stability through the IgG 1 hinge and Fc domain may be involved, although protein dimerization through the IgG 3 hinge domain did not reproduce this effect. The mechanism underlying this phenomenon, therefore, remains to be elucidated.
The causal mechanism for tolerance induction also requires more thorough investigation, although a number of factors may contribute to this effect, either alone or in combination. CTLA4-Ig fusion with antigen is of central importance, as we have never observed humoral tolerance without antigen fusion to this molecule. As discussed above, the enhanced levels of antigen expression through CTLA4-Ig fusion could be contributing to a high-dose tolerogenic effect. 33, 39, 40 Alternatively, CTLA4 negatively regulates T-lymphocyte activation through binding with B7 costimulatory molecules, 41, 42 and in this manner, CTLA4-Ig has been shown to prevent immunity through B7 blockade 27 and the upregulation of a tryptophancatabolizing pathway for tolerance induction. 32 Surprisingly, tolerance in this study was induced independently of CTLA4-Ig binding with B7 molecules as shown by mutating the MYPPPY-binding motif of the vector construct. CTLA4 also operates independently of B7 binding, 43, 44 and it will be interesting to determine whether tolerance can be induced by a vector encoding an Ig fusion molecule that lacks CTLA4, that is, rAAV-Ig-MSP4/5. Such a finding would create interesting parallels with other models of humoral tolerance either through B-lymphocyte expression of antigens fused to the N-terminus of IgG heavy chains, [45] [46] [47] or where the antibody isotype of the Ig fusion molecule is key to determine immunity or tolerance. 48 Collectively, these data support the conclusion that the mechanism underlying the tolerogenic effect of antigen fusion with CTLA4-Ig is multifactorial. Furthermore, on the basis of the report of Reitan and Hannestad, 48 our vector system would be rendered more immunogenic rather than tolerogenic through the use of an immunoglobulin isotype other than IgG1, or by removing the Fc portion of this molecule.
The capacity of rAAV to confer long-term transgene expression of foreign proteins in immunocompetent hosts is also likely to contribute to tolerance induction. 9, 10 The continued delivery of antigen in the absence of 'danger signaling' to the innate immune system is akin to the host's development of natural tolerance to endogenous proteins. 49 Indeed, we observed long-term expression of CTLA4-Ig fusion molecules, the levels of which 
were further elevated when CTLA4 was prevented from binding with B7 molecules. Presumably, 'wild-type' and mutated transgene products are differentially cleared by the immune system, either through sequestration by B7-expressing cell types or by antigen-specific antibodies. These hypotheses are supported by our study in immune deficient mice that showed reduced differences between the two vectors in respect of recombinant protein concentrations, but higher levels overall. An incidental observation made in the course of this experimentation is the dramatic spike in recombinant protein concentration observed 1 week after injection of the vector encoding the mutated B7-binding domain, which disappeared by the second week. The kinetics of this response closely mirror those of a recent report where transcriptionally active expression cassettes were detected shortly after rAAV delivery to the liver. 50 These were not sustained, however, because the provirus intermediates were deemed to be unstable. The dramatic appearance and disappearance of recombinant protein in this study may be through a similar mechanism.
In conclusion, we have shown that humoral tolerance or immunity can be specifically induced after intramuscular injection of rAAV vectors encoding CTLA4-Igfused antigens. Although this study has focused solely on humoral immunity, further investigation into the effects of these vectors on other immunological end points, such as cell-mediated effectors, may broaden the potential application of this system. To this end, the utility of these vectors for the more difficult task of extinguishing a preexisting immune response also needs to be investigated. Finally, the elucidation of the mechanisms responsible for these effects will enable further refinement of the vector to more efficiently regulate immunity or tolerance and increase the efficacy of rAAV as a gene therapeutic and vaccine platform.
Materials and methods
Mice and vaccinations
Eight to 10-week-old female Balb/C mice were purchased from the Animal Resource Centre (Canning Vale, Australia), whereas interleukin-2Rgc/
were bred in-house at the Children's Medical Research Institute. Mice were injected with rAAV vectors or recombinant protein emulsified in IFA as described previously. 26 
Cells and antibodies
HEK-293
52 and NIH3T3 53 were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Melbourne, Australia) supplemented with 2 mM glutamine and 10% heat-inactivated (30 min at 56 1C) fetal calf serum (SAFC Biosciences, Lenexa, KS, USA). Cultures were maintained at 37 1C in a 5% CO 2 humidified atmosphere. Plasmids encoding murine CD80 or CD86 (a gift from Dr JA Kantor, National Cancer Institute, Bethesda, MD, USA) were transfected by calcium phosphate precipitation 54 to HEK-293 cells, and genemodified cells were selected by culture in 600 mg ml 
Recombinant AAV vectors
Plasmids pTR-UF (a GFP-encoding AAV construct) and pTRMSP4/5 have been described earlier. 26, 56 Plasmids encoding the extracellular domain of murine CTLA4 fused with either the CH2/CH3 domains of human IgG 1 (pCTLA4-Ig_Rep7, 29 pCTLA4-h1gly_pCI, 30 ) or the hinge domain of human IgG 3 (pCTLA4-g3-OVA_pCi 31 ) were kindly provided by Professor A Lew (Walter and Eliza Hall Institute, Melbourne, Australia). Routine molecular biology protocols were used to subclone CTLA4-Ig or CTLA4-g3-OVA into the rAAV vector pTR-UF to replace the GFP and neomycin phosphotransferase expression cassettes to produce pTRCTLA4-Ig and pTRCTLA4-g3-OVA, respectively. These constructs encode a GGGT polylinker and MluI restriction site downstream of CTLA4-Ig to enable subcloning of antigenic sequences into the constructs. Sequences encoding MSP4/5 or HEL were PCR amplified and subcloned to pTRCTLA4-Ig to produce pTRCTLA4-Ig-MSP4/5 ( Figure 1 ) and pTRCTLA4-Ig-HEL, respectively. To produce a pTRCTLA4-Ig-MSP4/5 construct, lacking the intronic sequences, cDNA amplified by reverse trannscriptase PCR (RT-PCR; one Step RT-PCR kit, QIAGEN, Doncaster, Australia) from HEK-293 transfected with pTRCTLA4-Ig-MSP4/5 was restricted with Nhe I/BsrG I, and this fragment (728 bp) was ligated into Nhe I/BsrG Irestricted pTRCTLA4-Ig-MSP4/5. Plasmid pTRCTLA4-g3-MSP4/5 was produced by substituting the sequence encoding ovalbumin in pTRCTLA4-g3-OVA with that encoding MSP4/5. PCR primers 5 0 -ATGCTTAATTAAT GAGCCCAAATCTTGT-3 0 and 5 0 -ATGAACGATCGTGC CTCCT-3 0 were used to amplify the CH2 and CH3 domains of IgG 1 to produce a 682 bp product. This was restricted with Pac I and Pvu I and ligated with Pac I-restricted pTRMSP4/5 to produce pTR-Ig-MSP4/5. Tyrosine residues in the MYPPPY-binding motif of CTLA4 were mutated to alanine residues to prevent B7 binding, 57,58 using a QuikChange II Kit (Stratagene, Cedar Creek, TX, USA) with primer 5 0 -ACTCATGGCCC CACCGCCAGCCTTTGTGGGCATGG-3 0 and its reverse and complement primer as per the manufacturer's instructions. This kit was also used to mutate the histidine and glutamine amino acids at the respective positions of 310 and 311 in the IgG 1 molecule (numbered according to EU system, 59 ), which has been shown to prevent IgG-Fc interactions with FcRn, 37, 60 using the primer 5 0 -CTCACCGTCCTGGCCGACGACTGGCTGA ATG-3 0 and its reverse and complement primer. All constructs were validated by sequencing before use. Vectors were packaged into capsid serotype 1, for in vivo experiments, or capsid serotype 2, for in vitro experiments, using a helper virus-free system with the rAAV vaccines for humoral tolerance or immunity GJ Logan et al packaging plasmids pXR-1 or pXX2 and pXX6 as described earlier. 26 
In vitro vector function and B7-binding assay
To test vector functionality, crude vector preparations of rAAV in serotype 2 capsids were transduced to HEK-293 cells. After overnight incubation, transduced cells were harvested, washed and added to flasks in serum-free media and incubated for 48 h. Western analysis was performed on the processed culture supernatants as described earlier. 26 The capacity of recombinant CTLA4-Ig fusion molecules to bind B7 molecules was tested by mixing the equivalent of 10 mg protein from culture supernatants containing CTLA4-Ig fusion proteins (described above) with 1 Â 10 6 CD80 + -, CD86 + -or control HEK-293 cells in 200 ml ice-cold phosphate-buffered saline (PBS). Cells were mixed for 1 h at 4 1C and washed twice in ice-cold PBS before resuspension in 25 ml buffer (0.1 M NaCl, 0.01 M Tris.Cl (pH 7.6), 0.001 M EDTA (pH 8.0), 1 mg ml À1 aprotinin, 100 mg ml À1 PMSF, 0.1 M DTT). 5 Â loading buffer was added immediately and lysates were analyzed for MSP4/5 by western blot as described earlier. 26 Enzyme-linked immunosorbent assay to measure antibody responses, recombinant MSP4/5 or HEL Enzyme-linked immunosorbent assay for anti-MSP4/5 antibodies and specific isotype antibodies were performed as described earlier. 26 Antibodies to HEL or rAAV were similarly detected using recombinant HEL (Sigma-Aldrich) or CsCl-purified rAAV1-GFP (pTR-UF) as antigen. Primary antibodies were detected using goat anti-mouse Ig (Sigma-Aldrich) or goat anti-rabbit IgG (BioRad) conjugated with HRP followed by incubation in tetramethylbenzene (Sigma-Aldrich). Reactions were stopped using 2 M H 2 SO 4 and color absorbance was measured at 405 nm.
To measure the relative concentrations of recombinant MSP4/5 or HEL expressed from rAAV constructs, plasmids (5 mg or described equimolar equivalent) were transfected to cells by calcium phosphate precipitation 54 or lipofectamine (Invitrogen) as per the manufacturer's instructions. ELISA for recombinant MSP4/5 or HEL was performed in duplicate by incubating 96-well Maxisorp F96 ELISA plates (Nunc, Rosklide, Denmark) overnight with equivalent amounts of protein collected from culture supernatants of transfected cells. Wells were washed three times with PBS containing 0.05% Tween-20 (PBS-T) and blocked for 1 h at room temperature with 100 ml per well of PBS containing 5% skim milk powder (PBS-S). After three washes in PBS-T, wells received 100 ml of anti-MSP4/5 or anti-HEL antibody diluted in PBS-S (1:2000). Plates were incubated for 2 h at room temperature and washed three times in PBS-T. Primary antibodies were detected with 100 ml per well of HRP-conjugated goat antirabbit Ig (Sigma-Aldrich) diluted 1:2000 in PBS-S. After incubation at room temperature for 1 h and three washes in PBS-T, each well received 75 ml tetramethylbenzene. Plates were incubated at room temperature for 15 min, and the reaction was stopped by adding an equal volume of 2 M H 2 SO 4 . The absorbance of each well was measured at 450 nm and the mean of the duplicates was calculated. End point titers were determined on the basis of the highest dilution that produced an absorbance reading greater than three standard deviations above the mean of the blank.
RT-PCR detection of FcRn and MSP4/5 mRNA
Total RNA was isolated from HEK-293 and NIH3T3 cells using an RNeasy mini kit (QIAGEN) as per the manufacturer's instructions. RT-PCR for mRNA was performed using primers specific for human ( 
